Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

That is exactly what I wonder.

CTIX made a big point of announcing the extension , post phase 1, as an agreement with Dana Farber to look at other doses.

As I have just written I see a benefit to patients and to CTIX and to the shareholders should such dosing move forward with many different cancers- while we wait for the phase 2's to start. It is going to be a long time till we get data back from phase 2 with K plus irinotecan for pancreatic ca, for example, and yet we could have info by the end of this year about many targets- ovarian, pancreatic, renal- if they chose to do so.